Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 22, 2018 - Issue 1
Submit an article Journal homepage
883
Views
2
CrossRef citations to date
0
Altmetric
Editorial

Update on the role and therapeutic potential of polycomb repressive complexes in (biliary tract) cancer

Daniel NeureiterInstitute of Pathology, Paracelsus Medical University/Salzburger Landeskliniken, Salzburg, AustriaView further author information
,
Tobias KiesslichDepartment of Internal Medicine I, Paracelsus Medical University/Salzburger Landeskliniken and Laboratory for Tumour Biology and Experimental Therapies, Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, AustriaView further author information
,
Markus RitterLaboratory for Tumour Biology and Experimental Therapies & Laboratory for Functional and Molecular Membrane Physiology, Institute for Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, Austria;Department for Radon Therapy Research, Ludwig Boltzmann Cluster for Arthritis and Rehabilitation, Salzburg, AustriaView further author information
&
Christian MayrDepartment of Internal Medicine I, Paracelsus Medical University/Salzburger Landeskliniken and Laboratory for Tumour Biology and Experimental Therapies, Institute of Physiology and Pathophysiology, Paracelsus Medical University, Salzburg, AustriaCorrespondence[email protected]
View further author information
Pages 1-3 | Received 13 Sep 2017, Accepted 15 Nov 2017, Published online: 20 Nov 2017

References

  • Mayr C, Neureiter D, Wagner A, et al. The role of polycomb repressive complexes in biliary tract cancer. Expert Opin Ther Targets. 2015;19:363–375.
  • Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010;7:299–313.
  • Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383:2168–2179.
  • Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391–398.
  • Kreso A, Van Galen P, Pedley NM, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014;20:29–36.
  • Ma MZ, Chu BF, Zhang Y, et al. Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p. Cell Death Dis. 2015;6:e1583.
  • Mayr C, Wagner A, Loeffelberger M, et al. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget. 2016;7:745–758.
  • Zhang P, Guo Z, Wu Y, et al. Histone deacetylase inhibitors inhibit the proliferation of gallbladder carcinoma cells by suppressing AKT/mTOR signaling. PLoS One. 2015;10:e0136193.
  • Srinivasan M, Bharali DJ, Sudha T, et al. Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation. Oncotarget. 2017;8:38731–38742.
  • Bolomsky A, Schlangen K, Schreiner W, et al. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment. J Hematol Oncol. 2016;9:17.
  • Dimri M, Kang M, Dimri GP. A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells. Oncotarget. 2016;7:36220–36234.
  • Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14:275–291.
  • Zhang Z, Wang Q, Bu X, et al. Overexpression of Bmi1 promotes epithelialmesenchymal transition in CD133+Hep G2 cells. Mol Med Rep. 2017;16:6156–6161.
  • Jin X, Kim LJY, Wu Q, et al. Targeting glioma stem cells through combined BMI1 and EZH2 inhibition. Nat Med. 2017.
  • Mayr C, Ocker M, Ritter M, et al. Biliary tract cancer stem cells - translational options and challenges. World J Gastroenterol. 2017;23:2470–2482.
  • Sasaki M, Yamaguchi J, Ikeda H, et al. Polycomb group protein Bmi1 is overexpressed and essential in anchorage-independent colony formation, cell proliferation and repression of cellular senescence in cholangiocarcinoma: tissue and culture studies. Hum Pathol. 2009;40:1723–1730.
  • Mayr C, Beyreis M, Wagner A, et al. Deregulated MicroRNAs in biliary tract cancer: functional targets and potential biomarkers. Biomed Res Int. 2016;2016:4805270.
  • Urbas R, Mayr C, Klieser E, et al. Relevance of MicroRNA200 Family and MicroRNA205 for epithelial to mesenchymal transition and clinical outcome in biliary tract cancer patients. Int J Mol Sci. 2016;17(12).
  • Ma MZ, Li CX, Zhang Y, et al. Long non-coding RNA HOTAIR, a c-MYC activated driver of malignancy, negatively regulates miRNA-130a in gallbladder cancer. Mol Cancer. 2014;13:156.
  • Mayr C, Wagner A, Stoecklinger A, et al. 3-Deazaneplanocin A may directly target putative cancer stem cells in biliary tract cancer. Anticancer Res. 2015;35:4697–4705.
  • Gutschner T, Diederichs S. The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 2012;9:703–719.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.